- Increases insulin secretion.
- Inhibits sodium-glucose co-transporter 2 in the renal tubules, leading to increased glucose excretion in the urine.
- Decreases hepatic glucose production.
- Increases insulin sensitivity.
182. A patient with Type 2 Diabetes Mellitus is prescribed an SGLT2 inhibitor (e.g., empagliflozin). From a medicinal perspective, what is the technical pathophysiological mechanism of SGLT2 inhibitors?
Facebook
WhatsApp
